lutetium has been researched along with Cell Transformation, Neoplastic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ejeh, F; Brown, MP; Chenevix-Trench, G; Khanna, KK; Lakhani, SR; Miranda, M; Shi, W; Simpson, PT; Song, S; Swarbrick, A; Vargas, AC; Welm, AL; Wiegmans, AP | 1 |
| Cho, EH; Choi, SM; Kim, JJ; Lee, Sy; Lim, JC; Nam, SS; Park, SH; Park, UJ | 1 |
| Bäck, TA; Booth, GC; Fisher, DR; Frayo, SL; Frost, SH; Gopal, AK; Green, DJ; Hylarides, MD; Lin, Y; Miller, BW; Orozco, JJ; Pagel, JM; Press, OW | 1 |
| Cai, Z; Lu, Y; Pignol, JP; Reilly, RM; Winnik, MA; Yook, S | 1 |
| Cescato, R; Fani, M; Maecke, HR; Mueller, A; Nicolas, G; Reubi, JC; Rink, HR; Tamma, ML | 1 |
| Bao, A; Cheng, Z; Cochran, JR; Culter, CS; Jiang, L; Kimura, RH; Li, P; Liu, H; Miao, Z | 1 |
| Kjaer, A; Madsen, J; Persson, M; Ploug, M; Rasmussen, P | 1 |
| Müller, C; Schibli, R; Struthers, H; Winiger, C; Zhernosekov, K | 1 |
8 other study(ies) available for lutetium and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Topics: Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Inhibitors; ErbB Receptors; Female; Lutetium; Mice; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; RNA, Messenger | 2013 |
Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Topics: Amino Acids; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Lutetium; Male; Mice; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Tissue Distribution | 2015 |
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Topics: Animals; Antigens, CD20; Beta Particles; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Humans; Immunoconjugates; Lutetium; Lymphoma; Mice; Mice, Nude; Radioimmunotherapy; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2015 |
Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Topics: Animals; Brachytherapy; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Gold; Humans; Injections; Lutetium; Metal Nanoparticles; Mice; Neoadjuvant Therapy; Radioisotopes; Radiometry; Single Photon Emission Computed Tomography Computed Tomography | 2016 |
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Topics: Animals; Calcium; Cell Transformation, Neoplastic; CHO Cells; Cricetinae; Cricetulus; Drug Design; Enzyme Stability; Female; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; HEK293 Cells; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Mice; Neuroendocrine Tumors; Positron-Emission Tomography; Protein Transport; Radioactive Tracers; Radiography; Receptors, Somatostatin; Somatostatin; Structure-Activity Relationship; Tomography, Emission-Computed, Single-Photon | 2010 |
Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
Topics: Adult; Amino Acid Sequence; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Cystine-Knot Miniproteins; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Integrins; Lutetium; Male; Mice; Models, Molecular; Molecular Sequence Data; Platelet Membrane Glycoproteins; Protein Conformation; Radiation Dosage; Radiochemistry; Radioisotopes; Radiotherapy | 2011 |
New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Topics: Animals; Beta Particles; Cell Transformation, Neoplastic; Colorectal Neoplasms; Dideoxynucleosides; Female; Heterocyclic Compounds, 1-Ring; HT29 Cells; Humans; Lutetium; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Oligopeptides; Positron-Emission Tomography; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Substrate Specificity | 2012 |
DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Topics: Albumins; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Folic Acid; Heterocyclic Compounds, 1-Ring; Humans; KB Cells; Lutetium; Mice; Molecular Targeted Therapy; Multimodal Imaging; Positron-Emission Tomography; Radioisotopes; Tomography, X-Ray Computed | 2013 |